STOCK TITAN

Si-Bone - SIBN STOCK NEWS

Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.

Company Overview

Si-Bone Inc. is a specialized medical device company with a focused mission to improve patient outcomes in the realm of orthopedic surgery, particularly in the treatment of sacroiliac joint dysfunction. As a pioneer in the field, Si-Bone has developed a proprietary, minimally invasive implant system aimed at facilitating sacroiliac joint fusion. Leveraging patents for titanium implant technologies, the company has made significant strides in reducing the invasiveness of traditional sacroiliac joint fusion procedures.

Core Business and Innovation

At the heart of its operations, Si-Bone’s innovative approach is encapsulated in its iFuse Implant System, which is designed to provide a reliable alternative to conventional surgical techniques. The company has successfully combined advanced engineering with practical surgical approaches to produce a system that addresses complex conditions such as sacroiliac joint dysfunction, degenerative sacroiliitis, and pelvic trauma. The product portfolio includes instruments and implantable bone products that facilitate the fusion process during minimally invasive procedures, creating a distinct market niche with several industry-specific keywords such as minimally invasive surgery, orthopedic implants, and joint fusion.

Technological Advancements

Si-Bone separates itself from competitors through its commitment to technological innovation. The iFuse Implant System, along with its variations such as iFuse-TORQ and iFuse Bedrock Granite, incorporates breakthrough design and engineering principles to ensure safety and efficacy within complex anatomical regions. These devices are supported by rigorous clinical research and designed to provide enhanced pelvic fixation, particularly during concurrent lumbar spinal fusion procedures. This focus on precision technology underscores the company’s strategic positioning within the medical device market.

Clinical and Surgical Impact

The clinical implications of Si-Bone’s technology are noteworthy, especially for patients who have traditionally faced limited treatment options in the context of sacroiliac joint dysfunction. The minimally invasive nature of the iFuse Implant System offers advantages such as reduced recovery times, fewer complications compared to traditional open surgery, and a more targeted approach in addressing structural conditions. By improving the procedural experience for both patients and surgeons, Si-Bone plays a critical role in evolving standards of care in orthopedic surgery.

Market Position and Competitive Landscape

Si-Bone operates within a highly specialized sector of the medical device industry, marked by its focus on orthopedic applications. The company’s targeted approach to sacroiliac fusion procedures and its suite of patented implant products have carved a niche in an industry characterized by continuous innovation and rigorous safety standards. While there are other players in the broader field of orthopedic devices, Si-Bone differentiates itself by addressing the challenges associated with under-diagnosed and under-treated sacroiliac joint conditions using less invasive methods. The company’s seasoned management team, with experience from major industry names, further reinforces its authority and capability in driving orthopedic innovation.

Operational Excellence and Quality Assurance

Operating under stringent regulatory frameworks, Si-Bone emphasizes both the safety and effectiveness of its implant systems. The company’s operational strategy combines deep clinical expertise with advanced technological design, ensuring each product meets high standards of quality and efficacy. By integrating comprehensive research and development with real-world surgical feedback, Si-Bone is able to continuously refine its products, aiming to maintain robust patient safety profiles and reliable clinical outcomes.

Expertise and Industry Recognition

Si-Bone’s standing in the orthopedic device community is bolstered by its innovative approaches and the robust clinical data supporting its technologies. The company’s adoption of breakthrough design methods and its ability to translate complex medical needs into effective surgical solutions showcase its technical expertise. For healthcare professionals, patients, and stakeholders, Si-Bone represents a blend of advanced engineering, clinical precision, and a commitment to minimally invasive treatment paradigms, making it a respected name within its competitive landscape.

Comprehensive Product Portfolio

The diverse portfolio from Si-Bone is characterized by a range of implant systems designed to address various orthopedic conditions. It includes systems that directly target sacroiliac joint fusion as well as those that serve broader applications such as adjacent spinal conditions and pelvic trauma. This diversified approach allows clinicians to select devices tailored to the specific needs of their patients while maintaining consistency in surgical outcomes.

Conclusion

In summary, Si-Bone Inc. is an innovator in the orthopedic medical device space, focused on developing minimally invasive, patented implant systems for sacroiliac joint fusion and related applications. Through its continuous commitment to research, quality assurance, and operational precision, the company has established a strong market presence and a clear value proposition within a niche yet critically important segment of orthopedics. Its pioneering technologies, underscored by substantial clinical validation and a robust product portfolio, position it as an informative case study for anyone seeking a deep understanding of advanced orthopedic solutions.

Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN) has released promising 24-month results from the SALLY study, showcasing the efficacy of the iFuse-3D™ Implant System in treating sacroiliac joint pain. The study reported a significant decline in opioid use from 59% to 18% and consistent improvements in patient function and quality of life. This follows earlier studies endorsing the iFuse implant's safety and effectiveness. The iFuse-3D implant, designed for enhanced bone integration, is expected to further bolster the company's market position in the medical device sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
-
Rhea-AI Summary

SI-BONE, Inc. (SIBN) has launched the SI-BONE SImulator™, a revolutionary training simulation system for surgeons. This innovative platform is designed to enhance the learning of SI-BONE sacropelvic procedures, including iFuse procedures, using radiation-free technology. The SImulator can be utilized in various settings without traditional imaging equipment, making it accessible and portable. The collaboration with Medability has resulted in a versatile training tool that supports both group and individual training sessions and focuses on patient-specific anatomies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
none
-
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN) announced national reimbursement for the iFuse-3D Implant System™ by the French Health Ministry, effective June 1, 2021, for five years. This follows a positive opinion from the Haute Autorité de Santé recognizing the implant's therapeutic benefits for sacroiliac joint dysfunction. The implant is the first 3D-printed titanium solution for SI joint fusion, designed for effective bony integration. With reimbursement confirmed, patient access in France improves, allowing surgeons to leverage this technology for various pelvic and spinal conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
Rhea-AI Summary

SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2021 JMP Securities Life Sciences Conference. The company is set to present on June 17 at 2:30 p.m. ET. Interested parties can access a live and archived webcast on the company’s website. SI-BONE specializes in minimally invasive surgery of the SI joint with its iFuse Implant System, which has demonstrated effectiveness for treating chronic low back pain associated with sacroiliac joint dysfunction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
conferences
-
Rhea-AI Summary

SI-BONE, Inc. (SIBN) reported Q1 2021 revenue of $20.4 million, marking a 22% increase from Q1 2020. U.S. revenue reached $18.8 million, up 23% year-over-year. The company launched the iFuse-TORQ implant to address pelvic trauma needs and has transitioned its leadership team, appointing Laura Francis as CEO. Operating loss narrowed to $11.6 million from $11.9 million in 2020. Despite a cautious outlook due to COVID-19, SIBN anticipates 2021 revenue of $92 million to $94 million, projecting a 25% to 28% growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.23%
Tags
-
Rhea-AI Summary

SI-BONE, a medical device company focused on sacropelvic disorders, will participate in two key events: the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021, and the 2021 Bank of America Health Care Conference on May 12, 2021. During the Truist Securities event, management will host a Fireside Chat at 2:40 p.m. ET, and at the Bank of America Conference, they will present at 8:00 a.m. ET. Interested parties can view live and archived webcasts on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
conferences
Rhea-AI Summary

SI-BONE, Inc. (SIBN) announced significant leadership changes, appointing Anshul Maheshwari as Chief Financial Officer effective April 20, 2021. The transition also includes Laura Francis taking over as CEO, while Jeff Dunn remains Executive Chairman. Maheshwari brings over 15 years of experience, including his role at Varian Medical Systems. Additionally, Helen Loh and Laura Francis are new Board members, expected to enhance SI-BONE's strategy and marketing efforts. These changes aim to strengthen the company's growth and operational capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
management
-
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN) will report Q1 2021 financial results after market close on May 3, 2021. This announcement includes a conference call at 1:30 PM PT / 4:30 PM ET, accessible via phone or webcast on their website. The iFuse Implant System, the company's primary product for treating sacroiliac joint dysfunction, has shown positive clinical outcomes supported by multiple studies. Since 2009, iFuse has been the only SI joint fusion device with established insurance coverage based on its clinical effectiveness and safety.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences earnings
-
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq:SIBN) reported financial results for Q4 and FY 2020, showcasing a 12% increase in Q4 revenue to $22.1 million and a 9% increase for the year to $73.4 million. U.S. revenue grew 10% to $68.1 million for 2020. The company expects 2021 revenue guidance of $92 million to $94 million, reflecting projected growth of 25% to 28%. Operating loss stood at $7.9 million for Q4 and $38.6 million for the year. Cash and securities totaled $196.4 million as of Dec 31, 2020. The company continues to navigate challenges posed by the COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN) will announce its financial results for Q4 and full year 2020 on March 8, 2021, after market closure. A conference call will follow at 1:30 PM PT, available via phone and webcast. The company specializes in innovative minimally invasive surgery for sacroiliac joint disorders, particularly with its iFuse Implant System, which is backed by numerous clinical studies highlighting its effectiveness. This press release underscores SI-BONE's commitment to addressing chronic low back pain issues, along with its established insurance coverage for the iFuse procedure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
conferences earnings

FAQ

What is the current stock price of Si-Bone (SIBN)?

The current stock price of Si-Bone (SIBN) is $13.47 as of April 4, 2025.

What is the market cap of Si-Bone (SIBN)?

The market cap of Si-Bone (SIBN) is approximately 554.2M.

What is the primary focus of Si-Bone?

Si-Bone specializes in developing and commercializing innovative, minimally invasive implant systems designed for sacroiliac joint fusion, addressing complex orthopedic conditions.

How does the iFuse Implant System benefit patients?

The iFuse Implant System offers a less invasive alternative to traditional sacroiliac joint fusion surgery, resulting in reduced recovery times and potentially fewer complications.

What types of conditions does Si-Bone target with its products?

Si-Bone addresses conditions such as sacroiliac joint dysfunction, degenerative sacroiliitis, pelvic trauma, and specific challenges associated with spinal deformity.

How does Si-Bone differentiate itself in the orthopedic device industry?

Si-Bone differentiates itself by focusing on a niche market with its patented, minimally invasive technologies and by leveraging a management team with deep industry expertise from leading orthopedic companies.

What are the key benefits of minimally invasive surgical systems?

Minimally invasive systems typically provide improved patient recovery experiences, reduced overall surgical trauma, and enhanced precision during implant procedures, which are all hallmarks of Si-Bone's approach.

How does Si-Bone ensure the quality and safety of its products?

Si-Bone integrates rigorous clinical research and strict quality assurance protocols into its design and manufacturing process, ensuring that its implant systems meet high standards of safety and efficacy.
Si-Bone

Nasdaq:SIBN

SIBN Rankings

SIBN Stock Data

554.23M
37.70M
3.09%
95.51%
2.97%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA